Form 4: Aquestive Therapeutics Director Acquires Stock Options and Reports Common Stock Holdings

Aquestive Therapeutics, Inc. Director Gregory B. Brown reported the acquisition of 42,000 stock options and disclosed his beneficial ownership of 75,085 shares of common stock.

Summary

• Gregory B. Brown, a Director of Aquestive Therapeutics, Inc. (AQST), filed a Form 4 with the SEC.
• The filing reports a transaction dated June 11, 2025.
• Mr. Brown acquired 42,000 stock options with an exercise price of $3.41 per share.
• These options are scheduled to vest 100% on June 11, 2026, contingent upon Mr. Brown's continuous service with the company from the grant date through the vesting date.
• The acquired stock options have an expiration date of June 11, 2035.
• Following this reported transaction, Mr. Brown directly beneficially owns 75,085 shares of Aquestive Therapeutics Common Stock.
• He also directly beneficially owns 42,000 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally a positive signal, indicating alignment of interests and potential confidence in future company performance. It's a routine compensation event, but the insider's increased stake is a mild positive.

Positives

• Director Gregory B. Brown acquired 42,000 stock options, which aligns his interests with shareholder value as the options' profitability is tied to stock price appreciation.
• The grant of options suggests continued commitment and potential confidence from a key director in the company's future performance.

Risks

• The vesting of the 42,000 stock options is contingent upon Dr. Brown's continuous service with Aquestive Therapeutics, Inc. until June 11, 2026, meaning the options could be forfeited if service is terminated before this date.

Future Outlook

This Form 4 filing primarily reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's operational or financial performance, beyond the vesting schedule of the granted options.

Industry Context

This document is an insider transaction report (Form 4), which is a standard regulatory disclosure. The grant of stock options to a director is a common form of equity compensation in the pharmaceutical and biotechnology industries, aiming to align executive incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard practice for executive and board compensation across various industries, including biotechnology, to incentivize long-term performance and retention.
• The vesting schedule (100% after one year) is a common structure for such grants, though multi-year vesting is also prevalent.
• Without specific details on Aquestive Therapeutics' peer group compensation policies or the company's overall compensation philosophy, a direct comparison to specific industry benchmarks or comparable companies is not feasible based solely on this document.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns management's interests with shareholders, as the options' value increases with stock price appreciation, potentially incentivizing decisions that enhance shareholder returns.
• Employees: The vesting condition tied to continuous service is a standard practice in equity compensation, which can contribute to the retention of key personnel like directors.

Next Steps

• The 42,000 stock options granted to Gregory B. Brown are scheduled to vest on June 11, 2026, provided his continuous service with the Issuer is maintained.
• The options will remain exercisable until their expiration date of June 11, 2035.

Key Dates

Recommendation

Keywords

Aquestive Therapeutics, AQST, Form 4, Insider Transaction, Stock Options, Beneficial Ownership, Director, Equity Compensation, SEC Filing